PHILADELPHIA, PA — Tolerance Bio, Inc. has announced the completion of a $20.2 million seed financing round and the formation of a Scientific Advisory Board (SAB) to drive forward its innovative thymus cell therapy platform. The company is focused on developing allogeneic induced pluripotent stem cell (iPSC)-based therapies and pharmacological thymus treatments for immune-mediated diseases, including cancer, autoimmunity, and transplant rejection.
The oversubscribed financing round was led by Columbus Venture Partners and included investments from Criteria Bio Ventures, Pacific 8 Ventures, Sessa Capital, BioAdvance, Ben Franklin Technology Partners, and individual investors. The funding will support Tolerance Bio’s research and development efforts as it explores new approaches to immune tolerance and longevity.
“The Tolerance Bio team is humbled by the exceptional advisors and investors supporting our mission to preserve, restore and manipulate the thymus to address immune diseases and potentially increase longevity,” said Francisco Leon, M.D., Ph.D., Co-Founder and CEO of Tolerance Bio. “Each advisor is a leader in their respective fields, providing the Company with unbiased insights and guidance as we advance our programs in immunology, oncology, and beyond. We are incredibly excited by the opportunities lying ahead.”
The newly formed SAB includes renowned experts in immunology, stem cell therapy, and regenerative medicine, including Drs. Holger Russ, Megan Sykes, Camillo Ricordi, Jerome Ritz, Manasi Jaiman, and Roland Kolbeck. This assembly of scientific leaders will play a critical role in shaping Tolerance Bio’s efforts to address diseases caused by abnormal immune responses.
The company’s cutting-edge thymus therapy platform places Tolerance Bio at the forefront of immunology innovation, with potential breakthroughs that could provide new hope for patients suffering from a range of challenging immune-related conditions.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.